secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058254
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q3 2023 record revenue $211.7M; DAYBUE launch strong at $66.9M, NUPLAZID grows
--------------------------------------------------------------------------------

- Q3 total revenue $211.7M; DAYBUE net sales $66.9M (first full quarter), NUPLAZID $144.8M, up from $130.7M YoY
- Net loss $65.2M ($0.40 per share) vs $27.2M loss YoY; includes $100M upfront for worldwide DAYBUE rights
- Full-year 2023 guidance: NUPLAZID net sales $537.5-545M; R&D $340-350M; SG&A $390-400M
- Plans to start Phase 3 for ACP-101 (Prader-Willi) and Phase 2/3 for ACP-204 (Alzheimer's psychosis) in Q4 2023
- Appoints Albert Kildani as SVP IR and Stephanie Kim as SVP Regulatory Affairs

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/0000950170-23-058254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023058254/acad-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer